Newsroom | 67975 results

LONDON--(BUSINESS WIRE)--Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid technology. Callavid is a transformational leak-resistant medical device designed to address challenges associated with the se...

LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech announces the closing of a €12 million financing to advance a first-in-class DMOAD in the knee osteoarthritis...

MADISON, Wisconsin--(BUSINESS WIRE)--Die Promega Corporation führt eine neue Plattform für die Zielbindung in lebenden Zellen ein, die eine seit langem bestehende Kluft zwischen biochemischen und zellulären Assays für wenig erforschte oder schwer zu untersuchende Proteine schließen könnte. Das TarSeer™ BRETSA™ Target Engagement System ist ein neuartiger, auf Biolumineszenz-Resonanzenergietransfer basierender Shift-Assay zum Nachweis von Liganden-Protein-Wechselwirkungen in intakten Zellen unter...

MADISON, Wisconsin--(BUSINESS WIRE)--Promega Corporation lance une nouvelle plateforme d’engagement ciblé sur cellules vivantes qui pourrait combler un fossé de longue date entre les tests biochimiques et cellulaires pour les protéines peu étudiées ou difficiles à interroger. Le système d’engagement des cibles TarSeer™ BRETSA™ est un nouveau test de détection basé sur le transfert d’énergie par résonance bioluminescente qui permet de détecter les interactions entre les ligands et les protéines...

MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation lanceert een nieuw live-cell target engagement-platform dat een reeds lang bestaande leemte kan dichten tussen biochemische en cellulaire proeven voor te weinig bestudeerde of moeilijk te onderzoeken eiwitten. Het TarSeer™ BRETSA™ Target Engagement System is een nieuwe overdrachtstest gebaseerd op bioluminescentieresonantie-energieoverdracht voor het detecteren van ligand-eiwit interacties in intacte cellen door gebruik te maken van denaturati...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.78...

TOKYO & OSAKA, Japan--(BUSINESS WIRE)--Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service*1” designed to visualize a person’s immune status. Through the KIRIN HEALTH INNOVATION FUND, a corporate venture capital fund jointly established in February 2023 with Global Brain Corporation, one of Japan’s leading independent venture capital firms, Kirin Holdings invested in Immunosens*2 and has been e...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-984...

LUSSEMBURGO--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, partner di lunga data e affidabile per le soluzioni di studi clinici con una vasta esperienza nell'ambito di biomarcatori specifici e test molecolari, ha annunciato un'importante espansione del proprio portafoglio di servizi con l'aggiunta di capacità migliorate di test bioanalitici. Questi nuovi servizi sono in completa sintonia con le buone pratiche di laboratorio (GLP) e le buone pratiche cliniche (GCP), e consentiranno all'a...

CHANTILLY, Va.--(BUSINESS WIRE)--Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for the first quarter ended January 2, 2026, and reaffirmed its outlook for fiscal year 2026. “Amentum’s first-quarter results reflect solid operational performance and continued progress on our strategic objectives,” said Amentum Chief Executive Officer John Heller. “Robust bookings across our accelerating growth marke...